IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a note issued to investors on Thursday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

NASDAQ:IRIX opened at $1.50 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. IRIDEX has a fifty-two week low of $1.27 and a fifty-two week high of $3.65. The business has a 50 day moving average price of $1.68 and a 200-day moving average price of $1.74. The firm has a market cap of $24.96 million, a PE ratio of -2.24 and a beta of 0.84.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The business had revenue of $11.58 million for the quarter. During the same period last year, the firm earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.